A recent study published in the Journal of Pediatric Gastroenterology and Nutrition investigated non-inferiority of polyethylene glycol (PEG) 3350 with electrolytes (PEG3350+E) compared to PEG4000 without electrolytes (PEG4000). In this randomized double-blind trial, children between 0.5 and 16 years, with constipation defined as a defecation frequency of < 3 times per week, received either PEG3350 + E or PEG4000. Among the 82 children who completed the study, the mean reduction in total sum score (TSS) was -3.81 and -3.74 for PEG3350 + E and PEG4000, respectively. On the other hand, non-inferiority criteria were not met. In addition, daily sachet use was: 0 - 2 years: 0.4 - 2.3 and 0.9 - 2.1; 2 - 4y: 0.1 - 3.5 and 1.2 - 3.2; 4 - 8y: 1.1 - 2.8 and 0.7 - 3.8; 8 - 16y: 0.6 - 3.7 and 1.0 - 3.7, in PEG3350 + E and PEG4000, respectively. Overall, treatment success after 52 weeks was achieved in 50% and 45% of children, respectively. Moreover, rates of adverse events were similar between groups, and no drug-related serious adverse events occurred. Thus, the results indicated similar efficacy and safety of these agents.